July 2 (Reuters) - The U.S. Department of Justice
informed Viatris ( VTRS ) that it no longer considers Mylan a
subject of its antitrust investigation into the generic drug
industry, the company said on Tuesday.
Viatris ( VTRS ) was formed through the merger of Mylan and Pfizer's
Upjohn in 2020.